Why Specialize in Lower Doses?
THE NEED IS CLEAR
Higher doses of medication are not always more effective. Evidence shows the optimal dose for each patient varies. Lower doses are often associated with fewer side effects, and most importantly, improved outcomes and quality of life.
IT CAN BE DONE QUICKLY & EFFICIENTLY
Harnessing the body of evidence and the FDA's 505(b)(2) New Drug Application process, PRM Pharma is equipped to deliver new, lower-dose products of established pharmaceuticals quickly and efficiently, bringing optimal drug-dosing to the forefront of patient care.
Who We Are
PRM is a privately held, specialty pharmaceutical company committed to the development of lower-dose pharmaceuticals.
Our interest in lower-dose medications goes back to the 1990s. After 18 years in the pharmaceutical industry, working in R&D through Phase 4 clinical development, Joe McDevitt founded Grant Pharmaceutical, where his team developed the first low dose of a thiazide diuretic for the treatment of hypertension. That product, 12.5 mg hydrochlorothiazide (marketed as Microzide®), is currently one the most prescribed antihypertensive products in the United States.
Having sold Grant Pharmaceuticals to Watson Pharmaceuticals in 2002, Mr. McDevitt founded PRM Pharma, LCC, where he teamed up with leading experts to work on the development of lower dose formulations of additional established products.
Joseph T. McDevitt
PRESIDENT AND CEO
Melvin Sharoky, MD
HEAD, CORPORATE AND SCIENTIFIC AFFAIRS
Peter R. Kowey, MD
HEAD, CARDIOVASCULAR PRODUCTS
Deborah Maroko, MD
HEAD, MEDICAL AFFAIRS
Our Products
Coming Soon
In August 2023, PRM Pharma submitted a New Drug Application to the FDA for a new, low-dose antihypertensive drug. This lower dose product addresses the unmet clinical need for a specific dosage recommended for initial and add-on treatment of hypertension in current, evidence-based guidelines from leading cardiovascular health organizations.
